Vasoactive systems in L-NAME hypertension: the role of inducible nitric oxide synthase
Language English Country Netherlands Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Aorta drug effects metabolism physiopathology MeSH
- Time Factors MeSH
- Guanidines administration & dosage antagonists & inhibitors MeSH
- Hypertension enzymology physiopathology MeSH
- Enzyme Inhibitors administration & dosage pharmacology MeSH
- Injections, Intravenous MeSH
- Blood Pressure drug effects MeSH
- Rats MeSH
- Models, Cardiovascular MeSH
- Disease Models, Animal MeSH
- NG-Nitroarginine Methyl Ester administration & dosage antagonists & inhibitors MeSH
- Nitric Oxide metabolism MeSH
- Rats, Wistar MeSH
- Renin-Angiotensin System drug effects MeSH
- Heart Ventricles drug effects metabolism physiopathology MeSH
- Nitric Oxide Synthase Type II MeSH
- Nitric Oxide Synthase drug effects physiology MeSH
- Vasodilator Agents administration & dosage pharmacology MeSH
- Vasoconstriction drug effects MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Guanidines MeSH
- Enzyme Inhibitors MeSH
- NG-Nitroarginine Methyl Ester MeSH
- Nos2 protein, rat MeSH Browser
- Nitric Oxide MeSH
- pimagedine MeSH Browser
- Nitric Oxide Synthase Type II MeSH
- Nitric Oxide Synthase MeSH
- Vasodilator Agents MeSH
OBJECTIVES: The contribution of the renin-angiotensin system (RAS) and the sympathetic nervous system (SNS) to blood pressure (BP) maintenance was evaluated in rats with N(omega)-nitro-L-arginine methyl ester (L-NAME) hypertension. Furthermore, we studied the extent of nitric oxide (NO) synthesis inhibition and the participation of remaining NO in the counterbalance of pressor systems, with a special reference to inducible nitric oxide synthase (iNOS). METHODS: Wistar rats subjected to chronic L-NAME treatment (40 mg/kg per day for 4 weeks) were used. A consecutive blockade of RAS (captopril) and SNS (pentolinium) was followed by acute L-NAME injection. Dimethylguanidine or aminoguanidine were used to affect NO synthesis by iNOS. RESULTS: L-NAME hypertensive rats had borderline augmentation of depressor response to captopril injection, but their BP fall after pentolinium was considerably enhanced compared with controls. Residual BP (recorded after simultaneous blockade of the RAS and the SNS) was elevated by 20-40% in hypertensive rats. Pronounced inhibition of NO synthase activity (50% reduction in the aorta and myocardium) was detected in L-NAME hypertensive rats in which the BP rise elicited by acute L-NAME injection was considerably attenuated (by 60-80%). In contrast, acute administration of dimethylguanidine [mixed endothelial NO synthase (eNOS)/iNOS inhibitor] to hypertensive rats induced a major BP rise similar to that caused by L-NAME injection in controls. Aminoguanidine (a selective iNOS inhibitor) caused a substantial BP rise in L-NAME hypertensive rats only. CONCLUSION: The contribution of SNS to BP maintenance in L-NAME hypertension is more important than that of RAS. In L-NAME hypertensive rats the iNOS becomes a major source of hemodynamically important NO production, which is still insufficient to compensate prevailing vasoconstriction.
References provided by Crossref.org
Altered Balance between Vasoconstrictor and Vasodilator Systems in Experimental Hypertension
Research on Experimental Hypertension in Prague (1966-2009)
Nitric oxide and salt resistance in Dahl rats: no role of inducible NO synthase